NY-YUGO
11.10.2023 10:01:29 CEST | Business Wire | Press release
In a strategic move to further bolster its leadership team and drive its global expansion, Yugo, the first global student housing brand and operator announces the arrival of Joe Persechino as Chief Operating Officer (COO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231011144675/en/
Joe Persechino, Chief Operating Officer (COO), Yugo (Photo: Business Wire)
From London, Joe, with Yugo’s executive leaders, will optimise asset performance, customer engagement and loyalty through Yugo’s three core pillars –– YugoEco, YuPro, and YuGrow. Joe will focus on leading a world-class team to support Yugo’s objectives by attracting and developing top sales, marketing, and operational talent with a winning culture and mindset. He will also further integrate student market data and intelligence into Yugo's service offering to optimize customer and investor results.
Yugo’s mission is to support the student journey and Joe will further Yugo's commitment to delivering class leading student experiences. This includes the continuous evolution of Yuniverse, Yugo's technology stack to provide digital services with greater reach and connectivity to students globally.
Joe is a student and residential housing specialist with over 20 years of experience in global operational real estate. He brings a wealth of senior leadership experience across major markets such as USA and Europe, with a proven track record in developing businesses and teams to deliver operational results.
Joe joins from AXA IM Alts – Real Assets, where he was Head of Residential & Student Accommodation, responsible for strategy, deal origination and investment advice. Prior to that he held positions at Global Student Accommodation and Unite Group.
Christopher Holloway, a pivotal force behind Yugo’s growth, is promoted to Chief Business Development Officer (CBDO), to deliver on Yugo’s strategic growth plans, new market entry and integration. His key focus areas are third party management, executing on diversified strategies across operational, brand management and franchising.
Christopher has been in the industry for over 10 years and has been a pivotal part of Yugo’s journey since joining the group in 2012. Christopher has played an external role leading growth and is well known across the student accommodation sector. This move is testament to Christopher’s exemplary leadership, performance and strategic insight across the sector.
Rui Barros, Chief Executive Officer of Yugo, commented:
“I am delighted to welcome Joe to Yugo. His decades of experience across student and residential markets, from both the investor and operational perspective, will be invaluable as we continue to grow and strengthen the Yugo brand. Joe’s focus on operational excellence, with his track record developing businesses and high-performing teams, will be a tremendous asset.
Congratulations to Christopher on his well-deserved appointment to CBDO. Christopher has successfully driven Yugo forward into new markets and will continue as we expand our global reach, further solidifying our position as the leader in the global student housing market.
Both leaders will play critical roles in not only enhancing Yugo’s current offerings but also in paving the way for its future expansions and innovations, ensuring that Yugo continues to support the student journey with class-leading experiences.”
Joe Persechino, Chief Operations Officer, Yugo, said:
“I am delighted to be part of Yugo’s journey during this pivotal phase of its evolution. My prior experience as an investor combined with a decade plus of operational expertise, will provide knowledge to support Yugo’s future as the first global operational brand with class leading innovation and performance.”
Christopher Holloway, Chief Business Development Officer, Yugo, said:
“My priority is to lead global business development to new heights and work collaboratively with Yugo’s senior leadership to strategically deliver scale. Market conditions are presenting attractive opportunities across USA, Europe and APAC with Yugo well placed to unlock value for student housing partners.”
About Yugo
Yugo is the first global student housing brand and operator created to enhance students’ overall experiences throughout and beyond college life. Yugo offers a truly differentiated living experience that is environmentally and socially conscious, emotionally supportive, and safe.
Yugo is the operator of over 110 student living spaces located in nine countries with over 40,000 student beds in over 70 of the top cities in the world for higher education.
Yugo is part of The Dot Group, founded by Nicholas Porter, a pioneer in global student living with more than 30 years of experience.
Learn more at www.yugo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011144675/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom